Veterinary Antibiotics Market
Veterinary Antibiotics Market Size, Share & Industry Analysis, By Drug Class (Tetracyclines, Penicillins, Macrolides, Sulfonamides, Aminoglycosides, Others), By Animal Type (Livestock Animals, Companion Animals), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
“The global Veterinary Antibiotics Market is projected to grow at a CAGR of 3.7% from 2024 to 2031, reaching a value of USD YY by 2031.”
North America currently dominates the market, with key metrics indicating strong growth in livestock production and increasing pet ownership. The market is experiencing robust expansion driven by the rising demand for animal-based food products, growing awareness about animal health, and the emergence of new diseases in animals.
Veterinary Antibiotics Market Dynamics:
Market Trend: Increasing focus on developing alternatives to antibiotics and promoting responsible use
The veterinary antibiotics market is undergoing a substantial change towards discovering alternatives to existing antibiotics and promoting ethical use. This trend is being pushed by rising concerns about antimicrobial resistance (AMR) and the need for more sustainable animal health solutions. Manufacturers are investing in research and development of new alternatives such as prebiotics, probiotics, phytogenics, and immune modulators. For example, in 2023, a large animal health company stated that sales of antibiotic alternatives increased by 15% year on year.
Furthermore, many countries are enacting stronger laws regarding antibiotic usage in animals. The European Union, for example, outlawed the use of antibiotics for animal growth promotion in 2006, and similar regulations are being implemented worldwide.
Market Driver: Rising demand for animal-based food products and increasing livestock production
The growing worldwide population and rising disposable incomes in emerging nations are increasing demand for animal-based food items, which is boosting the veterinary antibiotics industry.
According to the Food and Agriculture Organisation (FAO), worldwide meat output is expected to rise 13% between 2020 and 2029, reaching 366 million tonnes. Antibiotics must be used for disease prevention and treatment in order to ensure animal health and productivity as livestock production increases. In the United States, for example, about 70% of all medically relevant antibiotics sold are used on food-producing animals. The expansion of farming operations to fulfill rising food demand heightens the need for efficient antibiotic treatments to manage and prevent disease outbreaks in big animal populations.
Market Restraint: Growing concerns over antimicrobial resistance and regulatory restrictions
The growing global worry about antimicrobial resistance (AMR) is a substantial challenge to the veterinary medicines market. Antibiotic abuse and misuse in animal husbandry have contributed to the evolution of resistant bacterial strains, which could possibly spread to humans via the food chain. This has resulted in tougher rules and standards for antibiotic usage in animals. For example, the United States Food and Drug Administration (FDA) enacted the veterinary Feed Directive (VFD) in 2017, which mandates veterinarian oversight for the use of medically essential antibiotics in animal feed. Such regulatory measures, while vital for public health, have the potential to hinder market growth by restricting the use of particular antibiotics in animal agriculture.
According to the World Health Organisation, the animal sector accounts for almost 80% of total consumption of medically relevant antibiotics in some countries, primarily for growth promotion in healthy animals, underscoring the industry's scale of difficulty.
Segment Overview:
The tetracyclines segment dominates the veterinary antibiotics market, driven by their broad-spectrum activity and cost-effectiveness in treating various animal diseases.
Tetracyclines dominate the veterinary antibiotics market due to their broad efficacy against both gram-positive and gram-negative bacteria, as well as their inexpensive cost. This antibiotic class is commonly used in livestock and companion animals to treat a wide range of illnesses, including respiratory, gastrointestinal, and skin infections. Tetracyclines are very popular in the livestock industry because they are effective at treating common diseases in cattle, pigs, and poultry.
Recent improvements in the tetracycline category have strengthened its market dominance. In 2023, a prominent animal health business produced a long-acting tetracycline formulation for cattle that provides prolonged therapeutic levels with a single treatment. This innovation has enhanced treatment compliance while reducing the need for multiple administrations, making it especially appealing for large-scale livestock operations.
The penicillins segment, albeit smaller than tetracyclines, is expanding steadily, notably in the companion animal market. Penicillins' effectiveness against many common bacterial illnesses in dogs and cats, combined with their low risk profile, makes them a popular choice among veterinarians treating home pets.
According to a recent veterinary medicine utilization assessment, penicillins will account for roughly 30% of antibiotic prescriptions for companion animals in Europe by 2023.
Regional Outlook:
North America leads the global veterinary antibiotics market, driven by a large livestock industry, high pet ownership rates, and advanced veterinary healthcare infrastructure.
North America's dominance in the veterinary antibiotics market is partly due to large-scale cattle production, high pet ownership rates, and a well-developed animal health business. The United States, in particular, makes a significant contribution to the region's market share. According to the USDA, the country had over 94 million cattle and calves as of January 2024, indicating a strong demand for veterinary antibiotics in the livestock sector.
Recent news emphasizes the region's ongoing leadership in veterinary antibiotic stewardship. The Food and Drug Administration (FDA) of the United States issued new guidelines for antibiotic usage in food-producing animals in early 2024, with the goal of encouraging more judicious use of medically necessary antibiotics. This development is predicted to influence market dynamics in the coming years, potentially increasing demand for alternative goods and more focused antibiotic therapy.
Key figures highlight North America's dominant position in the market. In 2023, the region represented nearly 40% of the worldwide veterinary antibiotics market. Furthermore, the American Pet Products Association estimated that 70% of U.S. households will own a pet in 2023, indicating a substantial market for companion animal antibiotics.
The companion animal sector in North America is a major driver of antibiotic use. With rising pet humanisation tendencies and a willingness to spend on pet healthcare, the demand for improved antimicrobial therapies for companion animals has increased. For example, the market for specialized antibiotic formulations for dogs, such as flavored tablets and long-acting injectable antibiotics, increased by 8% in 2023 over the previous year.
Competitive Intelligence:
The veterinary antibiotics market is dominated by a number of multinational pharmaceutical corporations and specialized animal health firms. Zoetis Inc., Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health, and Bayer Animal Health (now part of Elanco) are among the market's leading competitors, accounting for a sizable proportion.
Zoetis Inc., a key market player, reported $7.8 billion in annual revenue in 2023, with its anti-infectives portfolio accounting for a considerable portion of revenues. The company has been working on developing new antibiotic formulations and increasing its range of antibiotic alternatives. In 2023, Zoetis developed a novel vaccination for the prevention of bovine respiratory illness, with the goal of lowering the need for antibiotic treatments in cattle.
Boehringer Ingelheim Animal Health has prioritized research into innovative anti-infective therapies while also encouraging appropriate antibiotic use. The company's recent development of a digital health monitoring system for livestock intends to enable early disease identification and more focused antibiotic administration, which is consistent with the trend towards precision livestock production.
Merck Animal Health has been increasing its footprint in the companion animal market, with a particular emphasis on creating improved antibiotic formulations for pets. The company's recent acquisition of a pet health technology startup is intended to strengthen its ability to provide comprehensive health solutions for companion animals.
Looking ahead, the competitive landscape is anticipated to shift, with a greater emphasis on discovering antibiotic alternatives and promoting antibiotic stewardship. Companies are projected to increase their investment in research and development of novel anti-infective solutions such as vaccines, immunomodulators, and microbiome-based therapeutics.
Analyst Opinion:
The veterinary antibiotics market is at a crossroads, balancing the need for effective animal illness care against growing worries about antimicrobial resistance. Antibiotic use is expected to become more focused and responsible as a result of regulatory pressures and shifting consumer preferences.
The use of digital technologies in animal health management is a unique trend to follow. Some businesses are creating AI-powered diagnostic tools and wearable gadgets for animals to aid in early disease identification and more precise antibiotic administration. The integration of animal health and technology is likely to open up new commercial opportunities, particularly in developed nations where precision livestock production and enhanced pet care are becoming increasingly important.
Major Players:
-
Zoetis Inc.
-
Boehringer Ingelheim Animal Health
-
Merck Animal Health
-
Elanco Animal Health
-
Bayer Animal Health (now part of Elanco)
-
Virbac
-
Ceva Santé Animale
-
Vetoquinol S.A.
-
Dechra Pharmaceuticals PLC
-
Phibro Animal Health Corporation
Key Developments:
-
September 2024: Zoetis Inc. launches a new quick diagnostic tool for livestock that can diagnose bacterial illnesses and recommend appropriate antibiotic treatments within hours, with the goal of encouraging more focused antibiotic use in farm animals.
-
Merck Animal Health established a strategic alliance with a prominent biotechnology company in July 2024 to research novel antibiotic alternatives, with a focus on bacteriophage therapy to treat bacterial illnesses in cattle.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Zoetis Inc.
5.2. Boehringer Ingelheim Animal Health
5.3. Merck Animal Health
5.4. Elanco Animal Health
5.5. Bayer Animal Health (now part of Elanco)
5.6. Virbac
5.7. Ceva Santé Animale
5.8. Vetoquinol S.A.
5.9. Dechra Pharmaceuticals PLC
5.10. Phibro Animal Health Corporation (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Increasing focus on developing alternatives to antibiotics and promoting responsible use
6.1.2. Integration of digital technologies in animal health management
6.1.3. Growing demand for organic and antibiotic-free animal products
6.2. Market Drivers
6.2.1. Rising demand for animal-based food products and increasing livestock production
6.2.2. Growing pet ownership and expenditure on animal healthcare
6.2.3. Emergence of new animal diseases and zoonotic infections
6.3. Market Restraints
6.3.1. Growing concerns over antimicrobial resistance and regulatory restrictions
6.3.2. Increasing preference for vaccine-based disease prevention in animals
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Tetracyclines
7.1.1. Oxytetracycline
7.1.2. Doxycycline
7.2. Penicillins
7.2.1. Amoxicillin
7.2.2. Ampicillin
7.3. Macrolides
7.3.1. Tylosin
7.3.2. Tulathromycin
7.4. Sulfonamides
7.4.1. Sulfamethazine
7.4.2. Sulfadimethoxine
7.5. Aminoglycosides
7.5.1. Gentamicin
7.5.2. Neomycin
7.6. Others
7.6.1. Fluoroquinolones
7.6.2. Cephalosporins
8. BY ANIMAL TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Livestock Animals
8.1.1. Cattle
8.1.2. Swine
8.1.3. Poultry
8.1.4. Others
8.2. Companion Animals
8.2.1. Dogs
8.2.2. Cats
8.2.3. Others
9. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Oral
9.1.1. Tablets and capsules
9.1.2. Liquid formulations
9.2. Parenteral
9.2.1. Intravenous
9.2.2. Intramuscular
9.3. Topical
9.3.1. Creams and ointments
9.3.2. Sprays
10. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Veterinary Hospitals & Clinics
10.1.1. Standalone clinics
10.1.2. Hospital-affiliated clinics
10.2. Retail Pharmacies
10.2.1. Brick-and-mortar pharmacies
10.2.2. Online pharmacies
10.3. Others
10.3.1. Direct sales to farms
10.3.2. Feed mills
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Veterinary Antibiotics Market Segmentation:
By Drug Class:
-
Tetracyclines
-
Penicillins
-
Macrolides
-
Sulfonamides
-
Aminoglycosides
-
Others
By Animal Type:
-
Livestock Animals
-
Companion Animals
By Route of Administration:
-
Oral
-
Parenteral
-
Topical
By Distribution Channel:
-
Veterinary Hospitals & Clinics
-
Retail Pharmacies
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511